In B-ALL, case reports on the clinical activity of Aza [57–59] exist, and an ongoing clinical study applies Aza to the treatment of patients with B-ALL with KMT2A rearrangements (NCT02828358). The gene discussed is KMT2A; the disease is acute lymphoblastic leukemia.